Enhanced Eradication of Mucin-Embedded Bacterial Biofilm by Locally Delivered Antibiotics in Functionalized Microcontainers

Birk SE, Serioli L, Valentina Cavallo, Cavallo V, Haagensen JAJ, Janus Anders Juul Haagensen, Molin S, Nielsen LH, Zór K, Boisen A
Macromolecular bioscience · 2021 · vol. 21(8) , pp. e2100150 · doi:10.1002/mabi.202100150 · PMID:34117842
Other OA: closed
🔓 Open OA copy Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-10-08 ⓘ

Functionalized microcontainers loaded with ciprofloxacin and coated with chitosan and N-acetylcysteine significantly enhanced the eradication of mucin-embedded Pseudomonas aeruginosa biofilms compared to bolus antibiotic injection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-27 · read from full text ⓘ

This study investigates a novel drug delivery system using functionalized microcontainers loaded with ciprofloxacin and sealed with a chitosan and N-acetylcysteine lid to treat mucin-embedded bacterial biofilms. The researchers utilized a centrifugal microfluidic system to mimic the in vivo environment for Pseudomonas aeruginosa, demonstrating that the synergistic mucoadhesive and mucolytic properties of the coating significantly enhanced biofilm eradication compared to standard bolus injections or non-functionalized containers. The findings indicate that this targeted approach achieves rapid biomass killing within five hours while minimizing antibiotic usage. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Bacterial biofilm-related infections are difficult to eradicate and require repeated treatments with high doses of antibiotics. Thus, there is an urgent need for new treatment strategies that minimize the use of antibiotics while enhancing biofilm eradication. Functionalized reservoir-based microdevices, such as, microcontainers (MCs), offer, high drug loading capacity, mucus embedment, and tuneable drug release. Here, MCs are loaded with the antibiotic ciprofloxacin (CIP), and sealed with a lid consisting of chitosan (CHI) and a mucolytic agent, N-acetylcysteine (NAC). It is found that CHI and NAC work synergistically, showing improved mucoadhesive and mucolytic properties. To better mimic the in vivo habitat of Pseudomonas aeruginosa (P. aeruginosa), the biofilm is grown in a mucin-containing medium on a newly developed centrifugal microfluidic system. The CHI/NAC coated MCs improve eradication of biofilm (88.22 ± 2.89%) compared to CHI-coated MCs (72.68 ± 3.73%) or bolus injection (39.86 ± 13.28%). The findings suggest that MCs are significantly more efficient than a bolus treatment. Furthermore, CHI/NAC functionalized MCs kill most of the biomass already after 5 h (80.75 ± 3.50%), mainly due to a fast drug release. This is the first time that CHI/NAC has been combined as a coating to explore mucolytic properties on bacterial biofilms.
Full text 2,043 characters · extracted from oa-html · 2 sections · click to expand

Abstract

Bacterial biofilm-related infections are difficult to eradicate and require repeated treatments with high doses of antibiotics. Thus, there is an urgent need for new treatment strategies that minimize the use of antibiotics while enhancing biofilm eradication. Functionalized reservoir-based microdevices, such as, microcontainers (MCs), offer, high drug loading capacity, mucus embedment, and tuneable drug release. Here, MCs are loaded with the antibiotic ciprofloxacin (CIP), and sealed with a lid consisting of chitosan (CHI) and a mucolytic agent, N-acetylcysteine (NAC). It is found that CHI and NAC work synergistically, showing improved mucoadhesive and mucolytic properties. To better mimic the in vivo habitat of Pseudomonas aeruginosa (P. aeruginosa), the biofilm is grown in a mucin-containing medium on a newly developed centrifugal microfluidic system. The CHI/NAC coated MCs improve eradication of biofilm (88.22 ± 2.89%) compared to CHI-coated MCs (72.68 ± 3.73%) or bolus injection (39.86 ± 13.28%). The findings suggest that MCs are significantly more efficient than a bolus treatment. Furthermore, CHI/NAC functionalized MCs kill most of the biomass already after 5 h (80.75 ± 3.50%), mainly due to a fast drug release. This is the first time that CHI/NAC has been combined as a coating to explore mucolytic properties on bacterial biofilms. | Original language | English | |---|---| | Article number | 2100150 | | Journal | Macromolecular Bioscience | | Volume | 21 | | Issue number | 8 | | Number of pages | 10 | | ISSN | 1616-5187 | | DOIs | | | Publication status | Published - 2021 |

Keywords

- Artificial sputum medium - Chitosan - In vitro perfusion system - Microdevices - N-acetylcysteine - Pseudomonas aeruginosa biofilm Fingerprint Dive into the research topics of 'Enhanced Eradication of Mucin-Embedded Bacterial Biofilm by Locally Delivered Antibiotics in Functionalized Microcontainers'. Together they form a unique fingerprint.Cite this - APA - Author - BIBTEX - Harvard - Standard - RIS - Vancouver

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Anti-Bacterial Agents Anti-Bacterial Agents Anti-Bacterial Agents Mucins Biofilms Microbial Sensitivity Tests Pseudomonas aeruginosa

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
pubmed
last seen: 2026-10-08T21:31:13.178069+00:00
unpaywall
last seen: 2026-10-22T06:24:31.118836+00:00